Press Releases Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-07 pm EDT			5-day change	1st Jan Change
1.238 ^USD	-0.96%		-14.62%	-33.44%

Jun. 05	Adial Pharmaceuticals, Inc. Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder	CI
May. 14	Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder	Jun. 05	AQ
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th	May. 29	AQ
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	May. 15	AQ
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office	Apr. 22	AQ
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder	Apr. 10	AQ
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update	Apr. 02	AQ
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds	Mar. 04	AQ
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds	Mar. 01	AQ
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office	Feb. 28	AQ
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office	Feb. 13	AQ
Adial Announces Appointment of Tony Goodman as Chief Operating Officer	Jan. 18	AQ
Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate	Dec. 20	AQ
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement	Nov. 29	AQ
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 14	AQ
Adial Pharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K	Nov. 06	PU
Alcohol Use Disorder Pipeline \| Clinical Trials, Key Companies - Adial Pharmaceuticals, Arbor Pharmaceuticals, Gilead Sciences	Nov. 06	AQ
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss 'New Aspects in Substance Use Treatment' at the Annual International Society of Addiction Medicine Conference	Nov. 01	AQ
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference	23-10-31	AQ
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar	23-10-25	AQ
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules	23-10-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Press Releases

Filters